GFP
MNTA

Gryphon Financial Partners’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Gryphon Financial Partners’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,397
Closed -$29K – 918
2018
Q2 		$29K Sell
1,397
-34
-2% -$730 0.01% 320
2018
Q1 		$26K Sell
1,431
-175
-11% -$2.92K 0.01% 348
2017
Q4 		$22K Buy
+1,606
New +$21.7K 0.01% 388

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Gryphon Financial Partners's MNTA Position: Q3 2018 in Review

Gryphon Financial Partners sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2018, closing a stake of 1,397 shares — an estimated $29K sold.

Gryphon Financial Partners first reported a position in MNTA in Q4 2017 and held it in 3 quarters. The position peaked at $29K in Q2 2018. 159 funds tracked by Wall St. Rank hold MNTA as of Q3 2018.

  • Gryphon Financial Partners reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 1,397 Momenta Pharmaceuticals, Inc. shares in Q3 2018, an estimated $29K.
  • Gryphon Financial Partners first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Gryphon Financial Partners's Momenta Pharmaceuticals, Inc. position peaked at $29K in Q2 2018.
  • 159 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2018.

Based on Gryphon Financial Partners's 13F filing for Q3 2018, filed 6 Nov 2018.